NZ532625A

NZ532625A - Use of b-type natriuretic peptide as a prognostic indicator in acute coronary syndromes

Info

Publication number: NZ532625A
Application number: NZ532625A
Authority: NZ
Original assignee: Biosite Inc
Priority date: 2001-04-13
Filing date: 2002-04-11
Publication date: 2008-05-30

Abstract

Methods of determining a prognosis or a treatment regime for a patient diagnosed with an acute coronary syndrome comprising: contacting all or a portion of a sample from the patient with a first antibody that binds cardiac troponin I; contacting all or a portion of a sample from the patient with a second antibody that binds BNP and/or related markers related to BNP; determining the binding of the cardiac troponin I and the BNP and /or marker related to BNP to the first and second antibodies; and relating the binding to the patient's prognosis.

Description

<div class="application article clearfix" id="description"> 5326 2 5 NEW ZEALAND PATENTS ACT, 1953 No: Date: Divided out of New Zealand Specification No. 523210 dated 11 April 2002 COMPLETE SPECIFICATION USE OF B-TYPE NATRIURETIC PEPTIDE AS A PROGNOSTIC INDICATOR IN ACUTE CORONARY SYNDROMES We, BIOSITE INCORPORATED, 11030 Roselle Street, San Diego, CA 92121, USA, do hereby declare the invention for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement: -1 - (followed by page la) intellectual property office of n.z 28 APR 200*1 RECEIVED USE OF B-TYPE NATRIURETIC PEPTIDE AS A PROGNOSTIC INDICATOR — IN ACUTE CORONARY SYNDROMES This is a divisional of New Zealand Specification No. 523210. INTRODUCTION The present invention relates in part to methods, compositions, and devices for 5 the measurement of BNP, and the use of such measurement in the diagnosis, prognosis, and treatment of patients with acute coronary syndromes. BACKGROUND OF THE INVENTION The following discussion of the background of the invention is merely mitted t< provided to aid the reader in understanding the invention and is not admitted to , 10 describe or constitute prior art to the present invention. The term "acute coronary syndromes" ("ACS") has been applied to a group of coronary disorders that result from ischemic insult to the heart. Patients with ACS form * ' a heterogeneous group, with differences in pathophysiology, clinical presentation, and • - ■ i risk for adverse events. Such patients present to the physician with conditions that span ^ 15 a continuum that includes unstable angina, non-ST-elevation non-Q wave myocardial ^ infarction ("NST"-"MI"), ST-elevation non-Q wave MI, and transmural (Q-wave) MI. / ^ |1 ACS is believed to result largely from thrombus deposition and growth within one or | more coronary arteries, resulting in a partial or complete occlusion of the artery, and j frequently involves rupture of the plaque, resulting in an ischemic injury. ACS may / 20 also be precipitated by a coronary vasospasm or increased myocardial demand. For / review, see, e.g.j Davies, C/m. Cartfzo/. 20 (Supp. I): 12-17 (1997). The seriousness of ACS is underlined by the morbidity and mortality that follow the ischemic insult. For example, workers have estimated that within four to six weeks of presentation with ACS, the risk of death or a subsequent MI is 8-14%, and the rate of 25 death, MI, or refractory ischemia is 15-25%. Theroux and Fuster, Circulation 97: 1195-1206 (1998) Given that the total number of deaths in the U.S. from acute MI is about 600,000, the search within the art for information that relates to the diagnosis, prognosis, and management of ACS has understandably been extensive. Several potential markers that may provide such information in certain patient populations have 30 been identified, including circulating cardiac troponin levels {see, e.g., Antman et al., , N. Eng. J. Med. 335:1342-9 (1996); see also U.S. Patent Nos. 6,147,688,6,156,521, 5,947,124, and 5,795,725, each of which is hereby incorporated by reference in its la entirety), ST-segment depression (see, e.g., Savonitto et al., JAMA 281: 707-13 (1999)), circulating creatine kinase levels (see, e.g., Alexander et al, Circulation (Suppl.) 1629 (1998)), and circulating c-reactive protein levels (see, e.g., Morrow et al., J. Am. Coll. Cardiol. 31: 1460-5 (1998)). 5 B-type natriuretic peptide ("BNP" or "BNP-32") is a 32-amino acid neurohormone that is synthesized in ventricular myocardium and released into the circulation in response to ventricular dilation and pressure overload. The functions of BNP, like atrial natriuretic peptide, include natriuresis, vasodilation, inhibition of the renin-angiotensin-aldosterone axis, and inhibition of sympathetic nerve activity. The 10 plasma concentration of BNP is elevated among patients with congestive heart failure (CHF), and increases in proportion to the degree of left ventricular dysfunction and the severity of CHF symptoms. For review, see, e.g., Wiese et al., Circulation 102:3074-9 (2000); Yasue efal., Circulation 90:195-203 (1994); Yoshimura et al., Circulation 87: 464-9 (1993); Stein and Levin, Am. Heart J. 135: 914-23 (1998); and Ornland et al., 15 Heart 76:232-7 (1996). Th^ precursor to BNP is synthesized as a 108-amino acid molecule, referred to as " pre pro BNP," that is proteolytically processed into a 76-amino acid N-teiminal peptide (amino acids 1-76), referred to as "NT pro BNP" and the 32-amino acid mature hormone, referred to as BNP or BNP 32 (amino acids 77-108). It has been suggested 20 that each of these species - NT pro-BNP, BNP-32, and the pre pro BNP - can circulate in human plasma. See, e.g., Tateyama et al., Biochem. Biophys. Res. Commun. 185:760-7 (1992); Hunt et al., Biochem. Biophys. Res. Commun. 214: 1175-83 (1995). Pre pro BNP and NT pro BNP, and peptides which are derived from BNP, pre pro BNP and NT pro BNP that are present in the blood as a result of proteolyses of BNP, NT pro 25 BNP and pre pro BNP, are collectively described herein as "markers related to or associated with BNP." Following the onset of acute MI, the plasma concentration of BNP has been shown to rise rapidly over the first 24 hours, and then to stabilize; patients with large infarcts may have a second peak in BNP concentration several days later. The 30 concentration of BNP, when measured between 1 and 4 days following a transmural infarct, can provide prognostic information that is independent of the left ventricular ejection fraction (LVEF) and other important baseline variables. See, e.g., Talwar et al, Eur. Heart J. 21:1514-21 (2000); Darbar et al, Am. J. Cardiol. 78:284-7 (1996); 2 Richards et al., Heart 81:114-20 (1999); Omland et al, Circulation 93:1963-9 (1996); Arakawa et al., J. Am. Coll. Cardiol. 27:1656-61 (1996); and Richards et al., Circulation 97:1921-9 (1998). To date, however, studies evaluating the prognostic implications of increased 5 BMP concentration have been limited to patients with ST-elevation MI, and few data are available with regard to the prognostic implications of BNP following non ST-elevation acute coronary syndromes, including unstable angina and NST-MI. Thus, there remains in the art the need to identify markers useful in evaluating patient prognosis across the entire spectrum of acute coronary syndromes, so that patients at 10 risk of near-term morbidity or and/or death or can be identified and treated. It is an object of the present invention to go some way towards Mfilling this need and/or to provide the public with a useful choice. SUMMARY OF THE INVENTION The present invention relates to materials and procedures for evaluating the prognosis of patients suffering from acute coronary syndromes. In particular, the level of BNP in a patient sample, alone or in combination with one or more additional 15 prognostic markers, can provide prognostic information useful for predicting near-term morbidity and/or mortality across the entire spectrum of acute coronary syndromes. In various aspects, the invention relates to materials and procedures for identifying BNP levels, and/or levels of one or more markers related to BNP, that are associated with an increased predisposition to an adverse outcome in a patient; 20 identifying one or more additional prognostic markers that increase the predictive value of a BNP level, or of a marker related to BNP, for such an adverse outcome; using the BNP level, or the level of a marker related to BNP, in a patient, alone or in combination with one or more additional prognostic markers, to determine a patient's prognosis; and using the BNP level, or the level of a marker related to BNP, in a patient, alone or in 25 combination with one or more additional prognostic markers to determine a treatment regimen that improves a patient's prognosis. Thus, the materials and procedures described herein can be used to identify those patients that are at acute risk for one or more serious complications, including the~ risk of death, resulting from acute coronary syndromes, and to guide the clinician in 30 treatment of such patients. In a first aspect, the invention relates to methods for determining the prognosis of a patient diagnosed with an acute coronary syndrome. These methods comprise. 3 identifying a BNP level, or the level of a marker related to BNP, that is associated with an increased predisposition of an adverse outcome resulting from an acute coronary syndrome. Once such a prognostic level is determined, the level of BNP or a related marker, in a patient sample can be measured, and then compared to the prognostic level 5 that is associated with the increased predisposition of the adverse outcome. By correlating the patient level to the prognostic level, the prognosis of the patient can be determined. The term "BNP" as used herein refers to the mature 32-amino acid BNP molecule itself. As described herein, levels of BNP in patient samples can provide an 10 important prognostic indication of future morbidity and mortality in patients presenting with ACS. As the skilled artisan will recognize, however, other markers related to BNP may also serve as prognostic indicators in such patients. For example, BNP is synthesized as a 108-amino acid pre pro-BNP molecule that is proteolytically processed into a 76-amino acid "NT pro BNP" and the 32-amino acid BNP molecule. Because of 15 its relationship to BNP, the concentration of NT pro-BNP molecule can also provide prognostic information in patients. See, e.g., Fischer et al., Clin. Chem. 47: 591-594 (2001); Berger et al., J. Heart Lung Transplant. 20: 251- (2001). The phrase "marker related to BNP" refers to any polypeptide that originates from the pre pro-BNP molecule, other than the 32-amino acid BNP molecule itself. 20 Thus, a marker related to or associated with BNP includes the NT pro-BNP molecule, the pro domain, a fragment of BNP that is smaller than the entire 32-amino acid sequence, a fragment of pre pro-BNP other than BNP, and a fragment of the pro domain. One skilled in the art will also recognize that the circulation contains proteases which can proteolyze BNP and BNP related molecules and that these proteolyzed 25 molecules (peptides) are also considered to be "BNP related" and are additionally subjects of this invention. The phrase "determining the prognosis" as used herein refers to methods by which the skilled artisan can predict the course or outcome of a condition in a patient. The term "prognosis" does not refer to the ability to predict the course or outcome of a 30 condition with 100% accuracy, or even that a given course or outcome is more likely to occur than not. Instead, the skilled artisan will understand that the term "prognosis" refers to an increased probability that a certain course or outcome will occur; that is, that a course or outcome is more likely to occur in a patient exhibiting a given 4 characteristic, such as the presence or level of a prognostic indicator, when compared to those individuals not exhibiting the characteristic. For example, as described hereinafter, an ACS patient exhibiting a plasma BNP level greater than 80 pg/mL may be more likely to suffer from an adverse outcome than an AGS patient exhibiting a 5 lower plasma BNP level. For example, in individuals not exhibiting the condition, the chance of a certain course or outcome may be 3%. In such a case, the increased • probability that the course or outcome will occur would be any number greater than 3%. In preferred embodiments, a prognosis is about a 5% chance of a given outcome, about a 7% chance, about a 10% chance, about a 12% chance, about a 15% chance, 10 about a 20% chance, about a 25% chance, about a 30% chance, about a 40% chance, about a 50% chance, about a 60% chance, about a 75% chance, about a 90% chance, and about a 95% chance. The term "about" in this context refers to +/-1 %. A prognosis is often determined by examining one or more "prognostic indicators." These are markers, the presence or amount of which in a patient (or a 15 sample obtained from the patient) signal a probability that a given course or outcome will occur. For example, preferred prognostic indicators in the present invention aire BNP and markers related to BNP. As discussed herein, BNP is present in patients suffering from various acute coronary syndromes. When BNP reaches a sufficiently high level in samples obtained from such patients, the BNP level signals that the patient 20 is at an increased probability for morbidity or death, in comparison to a similar patient exhibiting a lower BNP level. A level of a prognostic indicator, such as BNP or a marker related to BNP, that signals an increased probability for morbidity or death is referred to as being "associated with an increased predisposition to an adverse outcome" in a patient. 25 The skilled artisan will understand that associating a prognostic indicator with a predisposition to an adverse outcome is a statistical analysis. For example, aBNP, or BNP-associated marker, level of greater than 80 pg/mL may signal that a patient is more likely to suffer from an adverse outcome than patients with a level less than or equal to 80 pg/mL, as determined by a level of statistical significance. Statistical 30 significance is often determined by comparing two or more populations, and determining a confidence interval and/or a p value. See, e.g., Dowdy and Wearden, Statistics for Research, John Wiley & Sons, New York, 1983. Preferred confidence intervals of the invention are 90%, 95%, 97.5%, 98%, 99%, 99.5%, 99.9% and 99.99%, 5 while preferred p values are 0.1, 0.05,0.025,0.02,0.01,0.005,0.001, and 0.0001. Exemplary statistical tests for associating a prognostic indicator with a predisposition to an adverse outcome are described hereinafter. The term "correlating," as used herein in reference to the use of prognostic indicators to determine a prognosis, refers to comparing the presence or amount of the prognostic indicator in a patient to its presence or amount in persons known to suffer from, or known to be at risk of, a given condition; or in persons known to be free of a given condition, jfcor example, a BNP level in a patient can be compared to a level r known to be associated with an increased disposition for an MI or death. The patient's BNP level is said to have been correlated with a prognosis; that is, the skilled artisan can use the patient's BNP level to determine the likelihood that the patient is at risk for an MI or death, and respond accordingly. Alternatively, the patient's BNP level can be f compared to a BNP level known to be associated with a good outcome (e.g., no MI, no death, etc.), and determine if the patient's prognosis is predisposed to the good outcome. In certain embodiments, a prognostic indicator is correlated to a patient prognosis by merely its presence or absence. For example, the presence or absence of ST-segment depression in an electrocardiogram can be correlated with a predisposition to certain conditions. See, e.g., Savonitto et al, JAMA 281: 707-13 (1999). In other embodiments, a threshold level of a prognostic indicator can be established, and the level of the indicator in a patient sample can simply be compared to the threshold level. For example, a BNP level of 80 or 100 pg/mL in a patient sample can be established as a level at which a patient is at an increased disposition for morbidity or death. A preferred threshold level for BNP or a BNP-associated marker of the invention is about 25 pg/mL, about 50 pg/mL, about 15 pg/mL, about 100 pg/mL, about 150 pg/mL, about 200 pg/mL, about 300 pg/mL, about 400 pg/mL, about 500 pg/mL, about 600 pg/mL, about 750 pg/mL, about 1000 pg/mL, and about 2500 pg/mL. The term "about" in this context refers to +/-10%. In yet other embodiments, a "nomogram" can be established, by which a level of a prognostic indicator can be directly related to an associated disposition towards a given outcome. The skilled artisan is acquainted with the use of such nomograms to relate two numeric values. The phrase "acute coronary syndromes" as used herein refers to a group of coronary disorders that result from ischemic insult to the heart. ACS includes unstable angina, non-ST-elevation non-Q wave MI, ST-elevation non-Q wave MI, and transmural (Q-wave) MI. ACS can be divided into non-ST-elevation ACS and ST-5 elevation ACS, each of which may be associated with certain prognostic indicators and prognoses, as described herein. The phrase "non-ST-elevation acute coronary syndrome" refers to those ACS not associated with an elevated ST component in an electrocardiogram. Non-ST-elevation ACS include unstable angina and non-ST-elevation non-Q wave MI. See, e.g., Nyman et al., Very early risk stratification by 10 electrocardiogram at rest in men with suspected unstable coronary heart disease. The RISC Study Group, J. Intern. Med. 1993; 234:293-301 (1993); Patel et alEarly continuous ST segment monitoring in unstable angina: prognostic value additional to the clinical characteristics and the admission electrocardiogram, Heart 75:222-28 (1996); Patel et al., Long-term prognosis in unstable angina. The importance of early 15 risk stratification using continuous ST segment monitoring, Eur. Heart J. 19:240-49 (1998); and Lloyd-Jones et al., Electrocardiographic and clinical predictors of acute myocardial infarction in patients with unstable angina pectoris, Am. J. Cardiol. 81: 1182-86 (1998), each of which is hereby incoiporated by reference in its entirety. Diagnosis of ACS generally, and non-ST-elevation ACS in particular, is well 20 known to the skilled artisan. See, e.g., Braunwald et ah, Unstable angina: diagnosis and management, Clinical practice guideline no. 10 (amended), AHCPR publication no. 94 0602. Rockville, Md.: Department of Health and Human Services, (1994); Yusuf et al., Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without ST elevation-25 OASIS (Organisation to Assess Strategies for Ischaemic Syndromes) Registry Investigators, Lancet 352:507-514 (1998); Savonitto et al., Prognostic value of the admission electrocardiogram in acute coronary syndromes, JAMA 281:707-713 (1999); Klootwijk and Hamm, Acute coronary syndromes: diagnosis, Lancet 353 (suppl IT): 10-15 (1999), each ofwhichis hereby incoiporated by reference in its entirety. 30 The phrase "adverse outcome" as used herein refers to morbidity or mortality suffered by a patient subsequent to the onset of ACS in the patient For example, a patient may present to a clinician with ACS; an adverse outcome could be a subsequent MI, subsequent onset of angina, subsequent onset of congestive heart failure, or 7 subsequent death. An adverse outcome is said to occur within the ''near term" if it occurs within about 10 months of the onset of ACS. In certain embodiments, one or more additional prognostic indicators can be combined with a level of BNP, or a related marker, in a patient sample to increase the 5 predictive value of BNP or the related marker as a prognostic indicator. The phrase "increases the predictive value" refers to the ability of two or more combined prognostic indicators to improve the ability to predict a given outcome, in comparison to a prediction obtained from any of the prognostic indicators alone. For example, a BNP level of X pg/mL may predict a 10% chance of a subsequent MI in die patient; 10 and a cardiac troponin I level of Y ng/mL may predict a 5% chance of a subsequent MI. But the presence of both a BNP level of X pg/mL and a cardiac troponin I level of Y ng/mL in sample(s) obtained from the same patient may indicate a much higher chance of a subsequent MI in die patient. Preferred additional prognostic indicators of the invention are circulating cardiac-specific troponin levels, ST-segment depression, 15 circulating creatine kinase levels, and circulating c-reactive protein levels. The skilled artisan will understand that the plurality of prognostic indicators , need not be determined in the same sample, or even at the same time. For example, one prognostic indicator may not appear in serum samples until some time has passed from the onset of ACS. Nevertheless, combining, for example, a cardiac troponin I level 20 taken at 1 hour with a BNP level obtained at 48 hours, may provide the skilled artisan with an increased predictive value in comparison to either measurement alone. Additionally, the increased predictive value need not be an increased probability of an adverse outcome. For example, a cardiac troponin I level taken at 1 hour may indicate a 5% chance of a subsequent MI. But when combined with a later BNP level 25 that indicates a good prognosis in the patient, the result may be to reduce the predicted chance that the patient will suffer a subsequent MI. The skilled artisan will also understand that a plurality of prognostic indicators may also include both a BNP level and the levels of one or more markers related to BNP; or, alternatively, may be two or more different markers related to BNP. For 30 example, the levels of BNP and NT pro-BNP may be combined to determine the prognosis of a patient with an increased predictive value in comparison to either measurement alone. 8 . The phrase "cardiac-specific troponin" refers to cardiac-specific isoforms of troponin I and T, and/or to complexes comprising at least one cardiac-specific troponin isoform. See, e.g., U.S. Patent Nos. 6,147,688,6,156,521,5,947,124, and 5,795,725, each of which is hereby incoiporated by reference in its entirety. Particularly preferred are methods that combine BNP and one or more cardiac-specific troponin isoforms as prognostic markers to determine the prognosis of a patient The term "patient sample" refers to a sample obtained from a living person for the purpose of diagnosis, prognosis, or evaluation. In certain embodiments, such a sample may be obtained for the purpose of determining the outcome of an ongoing condition or the effect of a treatment regimen on a condition. Preferred patient samples are blood samples, serum samples, plasma samples, cerebrospinal fluid, and urine samples. In another aspect, the invention relates to methods for determining a prognostic panel comprising a plurality of prognostic markers that can be used to determine the prognosis of a patient diagnosed with an acute coronary syndrome. These methods preferably comprise identifying a level of BNP, or a marker related to BNP, that is associated with an increased predisposition of an adverse outcome resulting from an acute coronary syndrome, and identifying one or more additional prognostic markers that increase the predictive value in comparison to that obtained from the use of BNP or the related marker alone as a prognostic indicator. Once the plurality of markers has been determined, the levels of the various markers making up the panel can be measured in one or more patient samplers), and then compared to the diagnostic levels determined for each marker, as described above. In yet another aspect, the invention relates to methods for determining a treatment regimen for use in a patient diagnosed with an acute coronary syndrome. The methods preferably comprise determining a level of one or more prognostic markers as described herein, and using the prognostic markers to determine a prognosis for a patient One or more treatment regimens that improve the patient's prognosis by reducing the increased disposition for an adverse outcome associated with the acute coronary syndrome can then be used to treat the patient. In a further aspect, the invention relates to kits for determining the prognosis of a patient diagnosed with an acute coronary syndrome. These kits preferably comprise devices and reagents for measuring a BNP level, or the level of a marker related to BNP, in a patient sample, and instructions for performing the assay. Optionally, the kits may contain one or more means for converting a BNP or related marker level to a prognosis. Additionally, the kits may provide devices and reagents for determining one or more additional prognostic markers to be combined with a level of BNP, or a marker 5 related to BNP, in a patient sample. BRIEF DESCRIPTION OF THE FIGURES Figure 1 shows Kaplan-Meier curves relating BNP concentration to 10-month mortality. Patients were divided into quartiles based on the concentration of BNP at enrollment 10 Figure 2 shows the association between BNP concentration and 10-month mortality. Patients were divided into quartiles based on the concentration of BNP at enrollment Quartiles were recalibrated for each of the subgroups shown. STEMI = ST elevation myocardial infarction; NSTEMI = non ST elevation myocardial infarction; UA = unstable angina. 15 Figure 3 shows a stepwise logistic regression model showing the relationship between selected baseline clinical variables and lOrmonth mortality. Cardiac troponin I (cTnl) and BNP quartiles were forced into the final model. Odds ratios and 95% confidence intervals are shown. In addition to the variables shown in the figure, the final model included history of hyperlipidemia or peripheral vascular disease; prior 20 therapy with diuretics, ACE inhibitors, nitrates, or heparin; heart rate; blood pressure; and creatinine clearance. Figure 4 shows the numbers of patients in 3 adverse outcome groups (death, congestive heart failure (CHF), and myocardial infarction (MI)) at 3 0 days and 10 months, among patients with a BNP concentration above and below a prespecified 25 threshold of 80 pg/mL. Figure 5 shows the relationship between BNP concentration and 10-month mortality, using a threshold of 80 pg/mL to define BNP elevation. STEMI = ST elevation myocardial infarction; NSTEMI = non ST elevation myocardial infarction; UA - unstable angina. 30 Figure 6 shows the numbers of patients in 3 adverse outcome groups (death, congestive heart failure (CHF), and myocardial infarction (MI)) at 30 days and 10 10 months, among patients with a BNP concentration above and below a. threshold of 100 pg/mL, Figure 7 shows the relationship between BNP concentration and 10-month mortality, using a threshold of 100 pg/mL to define BNP elevation. STEMI = ST 5 elevation myocardial infarction; NSTEACS = non ST elevation acute coronary syndrome; UA - unstable angina. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS Use of BNP as a prognostic marker in ACS As demonstrated herein, the concentration of BNP, measured in the first few 10 days after an acute coronary event, predicts the risk for morbidity and mortality across the entire spectrum of acute coronary syndromes. The prognostic utility of BNP persists after adjusting for clinical evidence of heart failure, as well as other important predictors of mortality, including clinical characteristics, ECG changes and cardiac troponin I. 15 Previous cohort studies have demonstrated that following acute MI, higher plasma concentrations of BNP and the N-terminal fragment of its prohormone (NT-pro BNP) are associated with larger infarct size (Arakawa et al., Cardiology 85:334-40 (1994); Horio et al., Am. Heart J. 126:293-9 (1993)), adverse ventricular remodeling (Nagaya et al., Am. Heart J. 135:21-8 (1998)), and lower ejection fraction and an 20 increased risk for the development of congestive heart failure aid death (Talwar et al., Eur. Heart J. 21; 1514-21 (2000); Darbar et al, Am. J. Cardiol 78: 284-7 (1996); Richards et al., Heart 81:114-20 (1999); Omland et al, Circulation 93:1963-9 (1996); Arakawa et al, J. Am. Coll. Cardiol. 27: 1656-61 (1996); Richards et al., Circulation 97: 1921-9 (1998)). These prior studies have each included fewer than 150 patients, and 25 focused on relatively homogenous groups of patients with ST elevation MI. The following exemplary embodiments extend these findings m patients with non-ST elevation acute coronary syndromes, including unstable angina. As demonstrated herein, a single measurement of BNP, performed a median of 40 hours after the onset of ischemic symptoms, provides powerful risk-stratification 30 across the entire spectrum of acute coronary syndromes. The prognostic implications of BNP levels are distinct from those of myocyte necrosis; that is, even among patients with unstable angina, the degree of BNP elevation is of prognostic significance. 11 Moreover, even after correcting for variables such as history of hypertension, heart failure, and prior diuretic or ACE inhibitor use, BNP remained predictive of long-term mortality. Thus, despite heterogeneity in pathophysiology and clinical presentation between patients with ST elevation ML, non-ST elevation ACS, and 5 unstable angina, increasing BNP concentration was predictive of mortality in each of these subgroups, suggesting that activation of the cardiac neurohormonal system may be a unifying feature among patients at high risk for death across the entire spectrum of acute coronary syndromes. " The association between BNP and long-term mortality was independent of 10 clinical evidence of congestive heart failure, as well as cardiac Troponin I, ECG changes, and other known predictors of mortality in ACS. In fact, BNP appeared to be a more powerful predictor of long-term mortality than any other variable measured. In addition, higher BNP levels Were associated with an increased risk for the development of nonfatal endpoints, including new or progressive heart failure and myocardial 15 infarction. Finally, it appears that a BNP threshold of 80 to 100 pg/mL, indicative of neurohormonal activation in patients with congestive heart failure, also performs well among patients with ACS. Also, unlike traditional cardiac biomarkers used to predict risk among patients with ACS, and particularly non-ST elevation ACS, BNP has a putative role in the 20 counter-regulatory response to ischemic injury. As such, it may act as an index of the size or severity of the ischemic insult, as well as the degree of underlying impairment in left ventricular function. For example, in an animal model of transmural myocardial infarction, BNP gene expression was augmented 3-fold in the left ventricle within 4 hours after the onset of coronary artery ligation, and importantly, tissue concentrations 25 of BNP were increased in non-infarcted as well as infarcted regions. Hama et al., Circu/ation 92:1558-64 (1995). Moreover, it has been demonstrated that BNP increases rapidly, and transiently, following exercise testing in patients with chronic stable angina, and that the degree of BNP elevation is closely correlated with the size of the ischemic territory as measured using nuclear SPECT imaging. Marumoto et al., 30 Clin. Sci. (Colch.) 88:551-6 (1995). Furthermore, BNP increases transiently following uncomplicated percutaneous transluminal coronary angioplasty even in the absence of changes in pulmonary capillary wedge pressure. Tateishi et al. Clin. Cardiol. 23: 776-80 (2000); Kyriakides 12 r et al, Clin. Cardiol 23:285-8 (2000). Several small cross-sectional studies have shown that BNP and Nt-pro BNP concentrations are higher among patients with unstable angina than among patients with stable angina or among healthy controls. Talwar et al, Heart 84: 421-4 (2000); Kikuta et al, Am. Heart J. 132:101-7 (1996). In 5 one of these studies (Kikuta et al.), BNP elevation appeared to correlate with echocardiograph findings of regional wall motion abnormalities but not with hemodynamic data obtained at the time of simultaneous cardiac catheterization; furthermore, after medical stabilization, wall motion abnormalities improved and BNP levels fell significantly. Taken together, these prior studies suggest that myocardial 10 ischemia may augment BNP synthesis and release, even in the absence of myocardial necrosis or pre-existing left ventricular dysfunction. Reversible ischemia may lead to a transient increase in left ventricular wall stress, which may be sufficient to cause BNP elevation. Use of BNP for determining a treatment regimen 15 A useful prognostic indicator such as BNP can help clinicians select between alternative therapeutic regimens. For example, patients with elevation in cardiac troponin T or I following an acute coronary syndrome appear to derive specific benefit from an early aggressive strategy that includes potent antiplatelet and antithrombotic therapy, and early revascularization Hamm et al., N. Engl. J. Med. 340:1623-9 (1999); 20 Morrow et al.,J. Am. Coll. Cardiol. 36:1812-7 (2000); Cannon et al, Am. J. Cardiol 82:731-6 (1998). Additionally, patients with elevation in C-reactive protein following myocardial infarction appear to derive particular benefit from HMG-CoA Reductase Inhibitor therapy. Ridker et al, Circulation 98: 839-44 (1998). Among patients with congestive heart failure, pilot studies suggest that ACE inhibitors may reduce BNP 25 levels in a dose dependent manner. Van Veldhuisen et al, J. Am. Coll. Cardiol 32:1811-8(1998). Similarly, "tailoring" diuretic and vasodilator therapy based on Nt-pro BNP levels may improve outcomes. Troughton et al, Lancet 355:1126-30 (2000). Finally, _ in a single pilot study of 16 patients found that randomization to an ACE inhibitor 30 rather than placebo following Q-wave MI was associated with reduced BNP levels over the subsequent 6-month period. Motwani et al, Lancet 341:1109-13 (1993). Because BNP is a counter-regulatory honnone with beneficial cardiac and renal effects, it is likely that a change in BNP concentration reflects improved ventricular function and 13 reduced ventricular wall stress. A recent article demonstrates the correlation of NT pro-BNP and BNP assays (Fischer et al, Clin. Chem. 47: 591-594 (2001). It is a further objective of this invention that the concentration of BNP can be used to guide diuretic and vasodilator therapy to improve patient outcome. Additionally, the measurement of 5 one or more markers related to BNP, such as NT-proBNP, for use as a prognostic indicator for patients suffering from acute coronary syndromes, is within the scope of the present invention. Recent studies in patients hospitalized with congestive heart failure suggest that serial BNP measurements may provide incremental prognositic information as 10 compared to a single measurement; that is, assays can demonstrate an improving prognosis when BNP falls after therapy than when it remains persistently elevated. Cheng et al., J. Am. Coll. Cardiol 37: 386-91 (2001). Thus, serial measurements may increase the.prognostic value of a marker in patients with non-ST elevation ACS as well. 15 Assay Measurement. Srategies Numerous methods mid devices are well known to the skilled artisan for measuring the prognostic indicators of the instant invention. With regard to polypeptides, such as BNP, in patient samples, immunoassay devices and methods are often used. See, e.g., U.S. Patents 6,143,576; 6,113,855; 6,019,944; 5,985,579; 20 5,947,124; 5,939,272; 5,922,615; 5,885,527; 5,851,776; 5,824,799; 5,679,526; 5,525,524; and 5,480,792, each of which is hereby incorporated by reference in its entirety, including all tables, figures and claims. These devices and methods can utilize labeled molecules in various sandwich, competitive, or non-competitive assay formats, to generate a signal that is related to the presence or amount of an analyte of interest. 25 Additionally, certain methods and devices, such as biosensors and optical immunoassays, may be employed to determine the presence or amount of analytes without the need for a labeled molecule. See, e.g., U.S. Patents 5,631,171; and 5,955,377, each of which is hereby incorporated by reference in its entirety, including all tables, figures and claims. 30 Examples The following examples serve to illustrate the present invention. These examples are in no way intended to limit the scope of the invention. 14 Example 1: Validation of BNP as a prognostic indicator in ACS Study Population The Oral Glycoprotein nb/EHa Inhibition with Orbofiban in Patients with Unstable Coronary Syndromes (OPUS-TIMI16) Trial was a randomized multicenter 5 trial comparing an oral glycoprotein Ilb/HIa inhibitor, orbofiban, with placebo in 10,288 patients with acute coronary syndromes. Patients Were included if they presented within 72 hours of the onset of ischemic discomfort and met one or more of the following criteria: dynamic ECG changes (ST deviation 0.5 mm, T-mm, T-wave inversion 3 mm in 3 leads, or left bundle branch block); positive cardiac markers; 10 prior history of coronary artery disease; or age 65 with evidence of diabetes or vascular disease. See, e.g., Cannon et al., Circulation 102:149-56 (2000). The study population described in the Examples herein consisted of a subpopulation of2525 patients from the OPUS-TIMI 16 study, of whom 825 were enrolled following an index ST elevation MI, 565 following a non-ST elevation MI, 15 and 1133 following a diagnosis of unstable angina. BNP concentration ranged from 0-1456 pg/mL, with a mean of 114 ± 3 pg/mL, a median of 81 pg/mL, and 25th and 75th percentiles of 44 and 138 pg/mL. Mean time from the onset of ischemic symptoms to randomization was 40 ± 20 hours (median 40 hours). Blood Sampling 20 Blood specimens were collected by trained study personnel in citrate tubes and centrifuged for 12 minutes. The plasma component was transferred into a sterile cryovial and frozen at -20° C or colder. Biochemical Analyses Troponin I, CKMB, CRP, and BNP were measured using standard 25 immunoassay techniques . These techniques involved the use of antibodies to specifically bind the protein targets. CRP was measured using the N Latex CRP assay (Dade Behring) and fibrinogen was assayed using the Dade Behring Assay on the BN H analyzer. In the case of BNP measurements, an antibody directed against BNP was biotinylated using N-hydroxysuccinimide biotin (NHS-biotin) at a ratio of about 5 30 NHS-biotin moieties per antibody. The biotinylated antibody was then added to wells of a standard avidin 384 well microliter plate, and biotinylated antibody not bound to 15 the plate was removed. This formed an anti-BNP solid phase in the microtiter plate. Another anti-BNP antibody was conjugated to alkaline phosphatase using standard techniques, using SMCC and SPDP (Pierce, Rockford, IL). The immunoassays were performed on a TECAN Genesis RSP 200/8 Workstation. The plasma samples (10 jjL) 5 were pipeted into the microtiter plate wells, and incubated for 60 min. The sample was then removed and the wells were washed with a wash buffer, consisting of 20 mM borate (pH 7.42) containing 150 mM NaCl, 0.1% sodium azide, and 0.02% Tween-20. The alkaline phosphatase-antibody conjugate was then added to the wells and incubated for an additional 60 min, after which time, the antibody conjugate was removed and the 10 wells were washed with a wash buffer. A substrate, (AttoPhos®, Promega, Madison, WI) was added to the wells, and the rate of formation of the fluorescent product was related to the concentration of the BNP in the patient samples. Clinical Endpoints All-cause mortality and nonfatal myocardial infarction were evaluated through 15 30 days, and the end of the follow up period (10 months). Myocardial infarction was defined using previously reported criteria based on CKMB elevation (Antman et al., Circulation 100:1593-601 (1999)), and all cases of suspected myocardial infarction were adjudicated by a Clinical Events Committee. The endpoint of new or worsening CHF or cardiogenic shock was collected from case record forms. 20 Statistical Analyses Subjects were divided into quartiles based on their concentration of BNP at the time of enrollment in the trial. Means and proportions for baseline variables were . compared across quartiles using ANOVA for continuous variables and the yl trend test for categorical variables. The direct correlation between BNP and other continuous 25 baseline variables was assessed using Pearson's test. Mean concentration of BNP was compared between patients who met a study endpoint and those who did not using the Student t test. Cox regression analysis was used to evaluate the association between increasing concentration of BNP and adverse cardiovascular outcomes through 30 days and 10 months. Stratified analyses were performed among patients with a 30 cTnl level > 0.1 ng/ml and a cTnl <0.1 ng/ml, as well as those with and without a clinical diagnosis of congestive heart failure. Subgroup analyses were performed in groups defined by the following index diagnoses: ST elevation MI, non-ST elevation 16 ACS, and unstable angina. Quartile ranges were recalculated for each of these subgroups. For the endpoint of all-cause mortality through the end of follow-up (10 months), a logistic regression model was constructed using forward stepwise selection. Clinical variables that were assessed in > 75% of the population were entered into the 5 model, provided they had a univariate p value < 0.1; variables were removed from the model if they had a multivariate p value >0.1. Baseline concentrations of cTnl and BNP were than forced into the completed model. Finally, analyses were performed using a BNP threshold of 80 and 100 pg/mL (Dao et al., J. Am. Coll. Cardiol 37: 379-85 (2001)). 10 Association with Baseline Clinical Variables In univariate analyses, higher baseline concentration of BNP was associated with older age, female sex, white race, and a prior history of hypertension, congestive heart failure, peripheral vascular disease, and cerebrovascular disease; BNP was inversely associated with history of hypercholesterolemia and current smoking 15 (table 1). As expected, BNP levels were highest among patients with ST elevation MI, intermediate among patients with non-ST elevation MI, and lowest among those with unstable angina (table 1). Patients with higher BNP concentrations were more likely to present in Killip Class II or greater, and were more likely to have ECG changes, elevations in cardiac biomarkers, and renal insufficiency. 20 Table 1 Baseline Clinical Characteristics According to Quartiles of BNP (pg/mL) Quartile 1 Quartile 2 Quartile 3 Quartile 4 p trend pQ4vs - " . ■- - ■ '•'■■■" ; ■ \ • : Qi Range of BNP levels, 0-43.6 43.7-81.2 81.3-137.8 137.9- pg/mL 1456.6 n 631 632 632 630 Time to 39 ±21 40 ±21 41 ±20 41 ±19 0.04 0.10 randomization (brs) Age (years) 57 ±10 59 ±11 61 ±12 66 ± 11 <0.0001 <0.0001 Male 474 (75%) 465 (74%) 472 (75%) 405 (64%) 0.0001 <0.0001 White 575(91%) 592(94%) 605(96%) 603(96%) 0.0002 0.001 17 Past Medical History Hypertension 246 (39%) 254 (40%) 263 (42%) 298 (47%) 0.003 0.003 Congestive Heart 26(4%) 28(4%) 26(4%) 56(9%) 0.0006 0.0008 Failure Coronary artery 329(52%) 312(49%) 294(47%) 327(52%) 0.7 0.9 disease Peripheral vascular 33(5%) 43(7%) 48 (8%) 57(9%) 0.008 0.009 disease Cerebrovascular 24(4%) 32(5%) 39(6%) 60 (10%) <0.0001 0.0001 disease Diabetes 138 (22%) 133 (21%) 132 (21%) 152 (24%) 0.4 0.3 199(32%) 191(30%) 173 (28%) 149 <24%) 0.0009 0.002 Hypercholesterolemia Smoking status: 0.0002 0.001 Current smoker 233 (37%) 263 (42%) 236(38%) 189 (30%) Never smoker 193 (31%) 161 (26%) 185 (29%) 254 (40%) Past smoker 204(32%) 205 (33%) 209 (33%) 186 (30%) Index Diagnosis: <0.0001 <0.0001 ST elevation MI 141(22%) 189(30%) 231 (37%) 264(42%) Non ST elevation 87(14%) 137(22%) 159 (25%) i82 (29%) MI Unstable angina 402(64%) 306(48%) 241 (38%) 184(29%) Physical findings BMIkg/m2 29 ±5 28 ± 5 28+14 28 ±12 0.1 0.08 Systolic BP (mm 130±20 129 ±19 128± 22 129 ±21 0.3 0.4 Hg) Killip Class n-IV 31(5%) 36(6%) 56(9%) 109 (18%) <0.0001 <0.0001 Diagnostic Testing Creatinine clearance 146 (24%) 185 (31%) 229 (38%) 350 (58%) <0.0001. <0.0001: <90 CK-MB > ULN 212 (58%) 308 (72%) 349 (79%) 388 (86%) <0.0001 <0.0001 ST depression > 270 (43%) 297 (47%) 311 (49%) 356 (57%) <0.0001 <0.0001 0.5mm * CAD=Prior coronaxy artery disease: previous MI, documented unstable angina, angina pectoris, angiographicaily confirmed CAD, prior PTCA or CABG not for index event. MT=myocardial infarction; BMI=Body Mass Index; ULN=upper limit of normal Although statistically significant, the associations between the baseline concentration of BNP and C-reactive protein (R=0.2; p<0.0001), Fibrinogen (R=0.18; 18 pO.OOOl), peak recorded CK-MB (R=0.09; p=0.0005) and LVEF (R=0.23; p<0.0001) were modest. Results from coronary arteriography, echocardiography, and exercise stress testing were available in a subset of the patient population. Higher BNP concentration was associated with more severe coronary disease, lower ejection . fraction, and a positive exercise stress test (p<0.01 for each; table 2). Table 2. Association between cardiac test results and BNP concentration Test 1. Result n BNP BNP (Mean + SD) p value Coronary Angiography: None 103 58 [32,111] 90 ±104 <0.0001 No. vessels with > 1 433 73 [41,118] 92 ±75 50% stenosis 2 368 70 [41,120] 104 ±112 405 93 [49,154] 136± 168 LV Ejection Fraction >50% 718 73 [41,128] 99 ±94 <0.0001 <50% 554 110 [59,184] 160± 182 Stress test Negative 374 65 [39,106] 91± 95 0.003 Indeterminate 118 88 [49,143] 118 ±128 Positive 296 88 [44,145] 118 + 118 LV=left ventricular, SD=standard deviation Clinical Outcomes Mean concentration of BNP was significantly higher among patients who died by 30 days (p<0.0001) or by 10 months (pO.OOOl) vs those who were alive at either time point (table 3). These differences remained significant in subgroups of patients with ST elevation MI, non-ST elevation ACS, and unstable angina (p<0.01 for each subgroup at both 30 days and 10 months; table 4). Mean BNP levels were significantly higher among patients with a myocardial infarction by 30 days (p=0.01) or 10 months (p=0.02), as compared with patients free of MI at these time points (table 3). Finally, BNP concentration was higher among patients who developed new or worsening CHF by 30 days (p<0.0001) or 10 months (p<0.0001) than among those who did not develop CHF, Table 3. Association between baseline BNP concentration (pg/mL) and outcomes Outcome n Median [25,75] Mean + SD p value* 30 days Dead 39 153 [79,294] 226 ±204 <0.0001 Alive 2486 80 [43,135] 113 ±124 MI 70 109 [50,159] 152 ±159 0.02 No MI 2455 80 [44,137] 113 ±125 CHF 43 159 [79,317] 252 ±269 <0.0001 No CHF 2482 80 [43,135] 112 ±121 0 months Dead 85 143 [88,308] 228 ±228 <0.0001 Alive 2440 79 [43,133] 110 ±120 MI 124 101 [50,161] 141 ±140 0.01 No MI 2401 80 [43,134] 113 ±126 CHF 78 158 [82,313] 256 ±278 <0.0001 No CHF 2447 79 [43,133] 110± 116 MI=myocardial infarction; CHF=new or worsening congestive heart failure, or cardiogenic shock; SD=standard deviation; *p value from Wilcoxon Rank Sum Test Unadjusted mortality increased in a stepwise direction across increasing quartiles of baseline BNP concentration (pO.OOOl: figure 1). These differences remained significant in subgroups of patients with ST elevation ML, non-ST elevation ACS, and unstable angina (p<0.02 for each; figure 1). In addition, the relationship between BNP and 10-month outcomes remained graded and significant both among patients with and those without history or exam evidence of CHF at enrollment (table 4). Table 4. Association between baseline BNP concentration (pg/ml) and 10-month outcomes in subgroups based on index diagnosis. Outcome n Median [25,75] Mean+SD - p value* ST elevation MI 825 96 [56,161] 131 + 125 Dead by 30 days Alive at 30 days 13 812 153 [77,265] 95 [56,161] 236 ±220 0.003 Dead by 10 months Alive at 10 months , 23 802 150 [90,227] 95 [55,161) 199 ±176 129 ±123 0.008 Non-ST elevation MI 565 98 [57,157] 136 ±148 Dead by 30 days Alive at 30 days 12 553 176 [149,327] 97 [56,155] 265 ±206 134 ±145 0.001 Dead by 10 months Alive at 10 months 28 537 176 [123,322] 95 [56,152] 245 ±176 131 ±144 <0.0001 Unstable Angina 1133 60 [33,105] 92 ±111 Dead by 30 days Alive at 30 days 14 1119 94[69,237] . 60 [33,105] 182 ±195 90 ±109 0.02 Dead by 10 months Alive at 10 months 34 1099 96 [70,265] 58 [33,104] ' 233 ±292 87 ±97 <0.0001 MD=myocardial infarction; SD=Standard deviation; *p value from Wilcoxon Rank Sum, Test When stratification was performed based on the concentration of cTnl at the time of enrollment, increasing BNP concentration remained associated with higher 10-month mortality, both among those with a cTnl <0.1 ng/mL (n=882; p=0.01) and those with a cTnl >0.1 ng/mL (n=1630; pO.OOOl) (figure 2). After adjustment for other independent predictors of long-term mortality, including ST deviation and cTnl, increasing concentration of BNP remained associated with a higher rate of death by 10 months (figure 3). The adjusted odds ratios for 10-month mortality wore 3.9 (1.1-13.6), 4.3 (1.3-15.0), and 6.7 (2.0-22.6) for patients with BNP concentrations in the second, 5 third, and fourth quartile, respectively (figure 3). Evaluation of 80 and 100 pg/mL BNP Threshold Analyses were performed using prospectively defined BNP thresholds of 80 and 100 pg/mL. Patients with a plasma concentration of BNP greater than 80 or 100 pg/mL were significantly more likely to suffer death, myocardial infarction, or 10 new/progressive CHF than those with a BNP level lower than the selected threshold (80 pg/mL threshold: p<0.005 for each at 30 days and 10 months; figure 4; 100 pg/mL threshold: p<0.005 for each at 30 days and 10 months; figure 6). In subgroups of patients with ST elevation MI, non-ST elevation ACS, and unstable angina, a BNP level greater than either 80 or 100 pg/mL was associated with a significant increase in 15 the risk for 10-month mortality (figures 5 and 7). While the invention has been described and exemplified in sufficient detail for those skilled in this art to make and use it, various alternatives, modifications, and improvements should be apparent without departing from the spirit and scope of the invention. 20 One skilled in the art readily appreciates that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The examples provided herein are representative of preferred embodiments, are exemplary, and are not intended as limitations pn the scope of the invention. Modifications therein and other uses will occur to those skilled in the art. 25 These modifications are encompassed within the spirit of the invention and are defined by the scope of the claims. It will be readily apparent to a person skilled in the art that varying substitutions and modifications may be made to the invention disclosed herein without departing -from the scope and spirit of the invention. 30 All patents and publications mentioned in the specification are indicative of the levels of those of ordinary skill in the art to which the invention pertains. All patents and publications are herein incoiporated by reference to the same extent as if each 22 individual publication was specifically and individually indicated to be incorporated by reference. The invention illustratively described herein suitably may be practiced in the absence of any element or elements, limitation or limitations which is not specifically disclosed herein. Thus, for example, in each instance herein any of the terms "comprising", "consisting essentially of' and "consisting of'may be replaced with either of the other two terms. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the appended claims. Other embodiments are set forth within the following claims. </div>

Claims

<div class="application article clearfix printTableText" id="claims"> WHAT WE CLAIM IS:

1. A method for determining a prognosis for a patient with an acute coronary syndrome, comprising contacting all or a portion of a sample from said patient with a first antibody that binds cardiac troponin I; contacting all or a portion of said sample with a second antibody that binds BNP and/or a marker related to BNP; determining the binding of said cardiac troponin I and said BNP and/or a marker related to BNP to said first and second antibodies; and relating said binding to the patient's prognosis.

2. A method for determining a prognosis for a patient with an acute coronary syndrome, comprising contacting all or a portion of a sample from said patient with a first antibody that binds cardiac troponin I or T; contacting all or a portion of said sample with a second antibody that binds NT-proBNP; determining the binding of said cardiac troponin I or T and said NT-proBNP to said first and second antibodies; and relating said binding to the patient's prognosis.

3. A method according to claim 1, wherein said first antibody binds free and complexed cardiac troponin I.

4. A method according to claim 1, wherein said second antibody binds BNP.

5. A method according to claim 1, wherein said second antibody binds NT-proBNP.

6. A method according to claim 1, wherein said second antibody binds proBNP.

7. A method according to claim 1, wherein said relating step comprises comparing a level of cardiac troponin I measured in said sample to a threshold level. 24 IPONZ 2 2 DEC 2005

8. A method according to claim 1, wherein said relating step comprises comparing a level of BNP and/or a marker related to BNP measured in said sample to a threshold level.

9. A method according to claim 2, wherein said first antibody binds free and complexed cardiac troponin T.

10. A method according to claim 2, wherein said first antibody binds free and complexed cardiac troponin I.

11. A method according to claim 2, wherein said relating step comprises comparing a level of cardiac troponin I or T measured in said sample to a threshold level.

12. A method according to claim 1, wherein said relating step comprises comparing a level of NT-proBNP measured in said sample to a threshold level.

13. A method according to claim 1 or 2, wherein said determining step comprises generating a signal from a sandwich immunoassay.

14. A method according to claim 1 or 2, wherein said sample is blood, serum, or plasma.

15. A method according to claim 1 or 2, wherein said prognosis is death.

16. A method according to claim 1 or 2, wherein said prognosis is congestive heart failure.

17. A method according to claim 1 or 2, wherein said prognosis is myocardial infarction.

18. A method according to claim 1 or 2, wherein the patient is diagnosed as having acute coronary syndrome (ACS).

19. A method according to claim 1 or 2, wherein the patient is diagnosed as having unstable angina.

20. A method according to claim 1 or 2, wherein the patient is diagnosed as having non-ST elevation non-Q wave myocardial infarction.

21. A method according to claim 1 or 2, wherein the patient is diagnosed as having ST-elevation non-Q wave myocardial infarction. 25 iponz 2 2 DEC 2005

22. A method according to claim 1 or 2, wherein the patient is diagnosed as having Q-wave myocardial infarction.

23. A method according to claim 1 or 2 substantially as herein described with reference to any example thereof and/or the accompanying drawings. Reference has been directed, in pursuance of section 16(1) of the Patents Act 1953, to patent number 523210 by the authority of the Commissioner of Patents. 26 </div>